Loading
Life sciences · Journal article
Materials Today Advances · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors (ICIs) represent a promising therapeutic strategy in bladder cancer (BCa), while limited response rates as monotherapy significantly restrict clinical application. To address this, we prepared QTANHOH, a quinoxalinone-based photosensitizer with histone deacetylases (HDACs)-targeting capability, for photoimmunotherapy in BCa. QTANHOH exhibited great phototoxicity under both normoxic and hypoxic conditions, alongside excellent bioavailability and high tumor specificity in BCa models. QTANHOH-mediated photodynamic therapy (PDT) effectively induced immunogenic cell death (ICD) in BCa cells and modulated the tumor microenvironment through localized treatment, enhancing therapeutic efficacy. Furthermore, combining QTANHOH-mediated PDT with immune checkpoint inhibitors (ICIs) synergistically improved photoimmunotherapy outcomes in BCa. This combination approach represents a promising strategy for augmenting immunotherapeutic responses in BCa through molecular-targeting photosensitizer.